Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Phase III BE SURE study of bimekizumab in plaque psoriasis meets coprimary endpoints

Dec. 9, 2019

Healthy volunteer safety data reported from phase IIb study of EB-01 in allergic contact dermatitis

Dec. 4, 2019

BiomX completes enrollment in cosmetic clinical study of BX-001 in acne-prone skin

Dec. 3, 2019

Aslan reports preliminary proof-of-concept data on ASLAN-004 in atopic dermatitis

Dec. 2, 2019

Lilly initiates phase II study of LY-3454738 in chronic spontaneous urticaria

Nov. 28, 2019

Pfizer initiates first-in-human study of PF-07038124

Nov. 22, 2019

Arcutis begins phase II study of ARQ-154 foam for seborrheic dermatitis

Nov. 21, 2019

Celldex begins phase Ia study with KIT inhibitor CDX-0159

Nov. 20, 2019

Positive results presented from second phase III psoriasis study of bimekizumab

Nov. 18, 2019

Long, low growth factor signaling promotes healing

Nov. 12, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...